Preferred Label : daclatasvir;
MeSH note : an HCV NS5A inhibitor; structure in first source;
CISMeF synonym : BMS-790052;
MeSH synonym : carbamic acid, N,N'-((1,1'-biphenyl)-4,4'-diylbis(1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-,
C,C'-dimethyl ester;
MeSH hyponym : BMS-790052-05;
MeSH Related Number : 50ZO25C11D;
Is substance : O;
UNII : LI2427F9CI;
Origin ID : C549273;
UMLS CUI : C3252090;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=42484
http://circulaire.legifrance.gouv.fr/pdf/2017/08/cir_42484.pdf
2017
false
false
false
France
French
legislation
insurance, health, reimbursement
hepatitis C, chronic
elbasvir-grazoprevir drug combination
dasabuvir
legislation, drug
antiviral agents
ritonavir
Product containing ombitasvir and paritaprevir and ritonavir in oral dose form (medicinal
product form)
ombitasvir
paritaprevir
direct acting antivirals
daclatasvir
administration, oral
Simeprevir
sofosbuvir-velpatasvir drug combination
ledipasvir, sofosbuvir drug combination
Multidisciplinary care conference (procedure)
Interdisciplinary medical team conference (procedure)
dasabuvir
ombitasvir
paritaprevir
daclatasvir
benzofurans
drug combinations
imidazoles
quinoxalines
Sofosbuvir
carbamates
Heterocyclic Compounds, 4 or More Rings
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
sulfonamides
uracil
uracil
anilides
macrocyclic compounds
---
http://www.has-sante.fr/portail/jcms/c_2728866/fr/reevaluation-des-antiviraux-d-action-directe-dans-le-traitement-de-l-hepatite-c
2016
false
false
false
France
French
guidelines for drug use
practice guideline
antiviral agents
hepatitis C, chronic
drug evaluation
Sofosbuvir
administration, oral
Simeprevir
direct acting antivirals
daclatasvir
ledipasvir
ledipasvir, sofosbuvir drug combination
drug therapy, combination
ritonavir
ombitasvir
paritaprevir
dasabuvir
drug resistance, viral
drug interactions
treatment outcome
daclatasvir
ombitasvir
paritaprevir
dasabuvir
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
imidazoles
anilides
carbamates
macrocyclic compounds
sulfonamides
uracil
uracil
---
http://www.has-sante.fr/portail/jcms/c_2633680/fr/antiviraux-d-action-directe
2016
false
false
false
France
French
evaluation of the transparency committee
adult
hepatitis C, chronic
drug therapy, combination
Sofosbuvir
antiviral agents
direct acting antivirals
daclatasvir
Simeprevir
ledipasvir, sofosbuvir drug combination
dasabuvir
drug combinations
ombitasvir
ritonavir
paritaprevir
fibrosis, liver
risk
has patient
hepacivirus
Infections
autoimmune diseases
hepatic fibrosis, nos
fibrosis
hepatitis C virus
human enterovirus 72
hepatitis C, chronic
business
liver cirrhosis
socialism
patients
chronic infectious disease
guideline
antiviral agents
chronic hepatitis, nos
health
case management
hepatitis c virus
hepatitis a virus
dasabuvir
ombitasvir
paritaprevir
daclatasvir
fibrosis
commerce
patients
guideline
benzimidazoles
fluorenes
uridine monophosphate
sulfonamides
uracil
uracil
anilides
carbamates
macrocyclic compounds
imidazoles
---
https://afef.asso.fr/wp-content/uploads/2018/06/VF-INTERACTIF-RECO-VHC-AFEF-v2103.pdf
http://www.infectiologie.com/UserFiles/File/medias/Recos/2015-juin-Recommandations-AFEF-Hepatite-C.pdf
2016
false
false
true
false
France
French
hepatitis C, chronic
practice guideline
severity of illness index
hepatitis C, chronic
antiviral agents
comorbidity
genotype
daclatasvir
ledipasvir
ribavirin
treatment outcome
drug resistance, viral
pregnancy
patient education as topic
liver cirrhosis
liver transplantation
recurrence
renal insufficiency
child
adolescent
drug users
hiv infections
acute disease
Acute hepatitis C
Simeprevir
Sofosbuvir
ledipasvir
ledipasvir, sofosbuvir drug combination
daclatasvir
imidazoles
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
---
http://www.has-sante.fr/portail/jcms/c_2621276/fr/daklinza
2016
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
daclatasvir
daclatasvir
antiviral agents
antiviral agents
drug therapy, combination
hepatitis C, chronic
adult
NS-5a protein, hepatitis C virus
continuity of patient care
insurance, health, reimbursement
Hepatitis C virus genotype 1 (organism)
Hepatitis C virus genotype 3 (organism)
Hepatitis C virus genotype 4 (organism)
daclatasvir
daclatasvir
daclatasvir
NS-5 protein, hepatitis C virus
imidazoles
viral nonstructural proteins
imidazoles
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00180
2015
false
false
false
false
Canada
French
drug information
daclatasvir
Product containing daclatasvir in oral dose form (medicinal product form)
daclatasvir
imidazoles
---
https://www.ema.europa.eu/medicines/human/EPAR/Daklinza
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
daclatasvir
daclatasvir
adult
hepatitis C, chronic
antiviral agents
antiviral agents
continuity of patient care
drug therapy, combination
administration, oral
tablets
NS-5 protein, hepatitis C virus
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
daclatasvir
daclatasvir
daclatasvir
viral nonstructural proteins
imidazoles
imidazoles
---
http://www.has-sante.fr/portail/jcms/c_2009488/fr/daklinza
http://www.has-sante.fr/portail/jcms/c_2009488/fr/daklinza-daclatasvir-antiviral-a-action-directe
2014
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
daclatasvir
daclatasvir
antiviral agents
antiviral agents
drug resistance, viral
drug therapy, combination
hepatitis C, chronic
adult
NS-5a protein, hepatitis C virus
continuity of patient care
insurance, health, reimbursement
guidelines for drug use
daclatasvir
daclatasvir
daclatasvir
NS-5 protein, hepatitis C virus
imidazoles
viral nonstructural proteins
imidazoles
---